Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2Head & Neck 1Gastrointestinal 1Classical hematology 1CNS 1

Conditions

Thrombocytopenia 1Neutropenia 1Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Breast Neoplasms 1Anemia 1

Interventions

Epoetin Alfa 6olaparib 5pegfilgrastim 3Filgrastim 3Carboplatin 3pembrolizumab 2pegylated granulocyte colony-stimulating factor 2palbociclib 2abemaciclib 2Tretinoin 2venetoclax 1trametinib 1talazoparib 1stinging nettle lectin 1ruxolitinib 1ribociclib 1regorafenib 1ponatinib 1pertuzumab 1peppermint oil 1neratinib 1lorlatinib 1lenvatinib 1idelalisib 1fludarabine phosphate 1enzalutamide 1entrectinib 1enasidenib 1durvalumab 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Moxibustion × Classical hematology × Clear all
NCT02781155 2016-05-24

Limiting Chemotherapy Side Effects by Using Moxa

East and North Hertfordshire NHS Trust

Phase 1/2 Unknown
25 enrolled
BreastClassical hematologyGastrointestinal

Anemia, Breast Neoplasms, Genital Neoplasms, Female, Neoplasms, Neutropenia, Thrombocytopenia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡